Filing Flows › Cryoport (CYRX) › Q3 2026 › vs Q3 2025
Cryoport (CYRX) Q3 2026 vs Q3 2025 (year over year)
Cryoport's revenue rose $6.0M (+14%) from $44.2M in Q3 2025 to $50.2M in Q3 2026. The biggest changes: Service +$4.3M (+18%); Product +$1.7M (+8%).
Cryoport, Q3 2026: revenue $50.2M (+14% year over year), operating margin -17.5%, net loss $10.9M, operating cash flow $5.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| BioLogistics Solutions | $22.5M | $19.4M | $3.1M | +16% |
| BioStorage/BioServices | $6.0M | $4.8M | $1.2M | +25% |
| Service | $28.6M | $24.3M | $4.3M | +18% |
| Product | $21.7M | $20.0M | $1.7M | +8% |
| Revenue | $50.2M | $44.2M | $6.0M | +14% |
| Net loss | $10.9M | $6.9M | $3.9M | +56% |
| Costs & expenses | $61.1M | $54.3M | $6.7M | +12% |
| Operating costs | $59.0M | $54.2M | $4.9M | +9% |
| Interest & other, net | $1.9M | −$3.2M | $5.0M | — |
| Income tax | $194K | $165K | $29K | +18% |
| Cost of revenue | $26.4M | $22.9M | $3.5M | +15% |
| Research & development | $4.7M | $4.5M | $211K | +5% |
| SG&A | $27.9M | $26.7M | $1.2M | +4% |
| Operating cash sources | $16.1M | $9.1M | $6.9M | +76% |
| Depreciation & amortization | $6.5M | $6.4M | $52K | +0.8% |
| Share-based compensation | $2.3M | $2.5M | −$180K | -7% |
| Working capital & other | $7.3M | $190K | $7.1M | 38× |
| Net loss absorbed | $10.9M | $6.9M | $3.9M | +56% |
| Operating cash flow | $5.2M | $2.2M | $3.0M | +138% |
| Capital expenditures | $5.3M | $3.5M | $1.8M | +52% |
| Negative free cash flow (OCF − capex) | $40K | $1.3M | −$1.2M | -97% |
Questions
How much did Cryoport's revenue grow year over year in Q3 2026?
Cryoport's revenue rose $6.0M (+14%) from $44.2M in Q3 2025 to $50.2M in Q3 2026.
What drove Cryoport's revenue change in Q3 2026?
Service +$4.3M (+18%); Product +$1.7M (+8%).